![Derek Gallacher](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Derek Gallacher
Corporate Officer/Principal bei Javelin Pharmaceuticals, Inc.
Profil
Derek Gallacher is a Managing Director of European for Javelin Pharmaceuticals, Inc. He was Director of European Analgesic Marketing and European Marketing Director for Mundipharma International Ltd.
Mr. Gallacher has 20 years of pharmaceutical experience.
Previously, he worked with Beecham and Glaxo Pharmaceuticals and Napp Pharmaceuticals Ltd.
Aktive Positionen von Derek Gallacher
Unternehmen | Position | Beginn |
---|---|---|
Javelin Pharmaceuticals, Inc.
![]() Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Javelin Pharmaceuticals, Inc.
![]() Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | Health Technology |